10 Key Insights From PharmaBoardroom Contributors in 2019

face
main_img

2019 was a year of innovation and disruption in the life sciences industry. From artificial intelligence to cell and gene therapy, and from generics and biosimilars to geopolitics and healthcare reform, PharmaBoardroom is proud to have collaborated with industry thought leaders to publish their insights on the year’s top trends in pharma and healthcare. Here we present ten opinion pieces published in 2019. Read more from our contributors here.

 

Three Basic Truths About the US Healthcare System

AstraZeneca’s Senior Vice President of US Market Access Rick R. Suarez takes a deeper look at US healthcare system challenges and suggests that cross-sector collaboration, rather than blame-shifting, is what will effect positive change.

Three Basic Truths About the US Healthcare System

 

The Cell & Gene Therapy Market: Coming into Its Own

David H. Crean is the managing director for Objective Capital Partners, a middle market investment banking firm located in Southern California, where he leads the firm’s M&A, partnering and capital financing transactions with life science and healthcare clients. In this article Crean highlights trends in the cell and gene therapy market and why now is the time to invest in these cutting-edge treatments.

The Cell & Gene Therapy Market: Coming into Its Own

 

Forging a New Path to Commercialization for Cell and Gene Therapies

In a similar vein, Greg Reh, Global Life Sciences & Health Care industry leader for Deloitte,  shares how pharma companies should prepare for innovations in the manufacturing, pricing and reimbursement of personalized cell and gene therapies and the challenges these disruptive innovations will present.

Forging a New Path to Commercialization for Cell and Gene Therapies

 

From Hype to Health: Delivering on the Promise of AI in Biopharma

Krishna Cheriath serves as chief data officer at Bristol-Myers Squibb. Cheriath is the company’s data strategist and adviser, steward for improving data quality, an evangelist for data sharing, data-driven innovations and data ethics and standards, and lead technologist for data and analytic automation. From this vantage point he has observed the gradual adoption of artificial intelligence in healthcare and has seen how AI is already transforming the industry.

From Hype to Health: Delivering on the Promise of AI in Biopharma

 

Real-World Evidence – A Game Changer for Pharma

Nawal Roy is the founder and CEO of Holmusk, a company dedicated to building one of the world’s largest real-world evidence platforms for neurosciences. Roy discusses tangible ways that pharmaceutical companies can use real-world evidence to increase effectiveness in product life-cycle management.

Real-World Evidence – A Game Changer for Pharma

 

Proposed Solutions to the Access Challenges Facing Cancer Medicines in Europe

Janssen’s EMEA market access head Martin Price  leads the teams responsible for achieving optimal and accelerated market access, at a fair and value-based price, for Janssen’s new products and indications. In this article Price outlines access challenges that cancer patients in Europe face, including time between regulatory approval and patient access as well as barriers to timely reimbursement. Price suggests some regulatory changes that should be made in order to speed up access to transformational cancer therapies.

 

Proposed Solutions to the Access Challenges Facing Cancer Medicines in Europe

 

USA: The Biosimilars Trade Opportunity

Chester “Chip” Davis, Jr. is the President and Chief Executive Officer of the Association for Accessible Medicines (AAM), the nation’s leading trade association for manufacturers and distributors of generic prescription drugs, manufacturers of bulk active pharmaceutical chemicals and suppliers of other goods and services to the generic drug industry. Continuing on the topic of patient access, Davis argues for greater provision for access to affordable medicines – including biosimilars – within the trade agreements, and how such provisions would bolster the development of biosimilars.

USA: The Biosimilars Trade Opportunity

 

Japan: Reforming Healthcare in the Age of Ageing

Asia also faces a growing need to increase patient access to innovative medicines and in Japan, this need is related to its ageing population. Janssen Japan’s Chris Hourigan makes the case for increasing access to innovative medicines to combat escalating healthcare costs.

Japan: Reforming Healthcare in the Age of Ageing

 

Why Invest in Rare Diseases & Orphan Drugs?

David H. Crean of Objective Capital Partners makes the case for why orphan drugs deserve to be invested in, taking a look at the forecast of orphan drug sales over the next five years. Crean also highlights companies currently leading the rare disease drug market.

Why Invest in Rare Diseases & Orphan Drugs?

 

The Ideal Pharma Country Manager: China

Lydia GuoGrace Zhao and Mendy Zhang of executive search firm Egon Zehnder outline why country managers of multinational pharma affiliates should exhibit curiosity, insight, engagement and determination and highlight some of the latest trends affecting the Chinese pharma sector.

The Ideal Pharma Country Manager: China (Egon Zehnder)

Tags:

Add Your Comment


You must be logged in to post a comment.

Related Content

Latest Report